Drug Exposure in Musculoskeletal Disease: Pathophysiology, Clinical Impact, and Therapeutic Advances

Abstract

Musculoskeletal diseases (MSDs) represent a significant source of morbidity and disability worldwide. Drug exposure, whether as a direct etiological factor, disease modifier, or therapeutic agent, critically shapes the clinical course and management of MSDs. This review synthesizes current evidence on the interplay between pharmacological agents and musculoskeletal health, addressing epidemiology, pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, and therapeutic considerations. Emphasis is placed on the clinical implications of common drugs, adverse musculoskeletal effects, and recent advances in targeted therapies. The review integrates guideline-based recommendations and emerging research to inform best practices for clinicians managing MSDs in the context of drug exposure.

Introduction

Musculoskeletal diseases encompass a diverse spectrum of disorders affecting bones, joints, muscles, and connective tissues. The global burden of MSDs is escalating due to aging populations, lifestyle changes, and expanded pharmacotherapeutic options. Drug exposure plays a multifaceted role—certain agents may precipitate or exacerbate musculoskeletal pathology, while others offer disease-modifying benefits. Understanding the nuanced relationship between drugs and musculoskeletal tissues is essential for optimizing patient outcomes, minimizing iatrogenic harm, and advancing precision medicine in rheumatology, orthopedics, and rehabilitation.

Epidemiology / Disease Burden

MSDs are among the leading causes of disability-adjusted life years (DALYs) globally, with osteoarthritis, rheumatoid arthritis, osteoporosis, and back pain dominating prevalence statistics. Medications such as corticosteroids, statins, aromatase inhibitors, and fluoroquinolones are frequently implicated in drug-induced musculoskeletal complaints, ranging from myalgias to severe conditions like osteonecrosis or tendon rupture. Polypharmacy, particularly in elderly and multimorbid populations, increases susceptibility to adverse drug events affecting the musculoskeletal system, thereby compounding the disease burden and healthcare utilization.

Pathophysiology

The pathophysiological impact of drug exposure on musculoskeletal tissues varies by agent and underlying host factors. Corticosteroids accelerate bone resorption by upregulating RANKL and suppressing osteoblast function, predisposing to osteoporosis and fractures. Statins may induce myopathy through mitochondrial dysfunction and impaired protein synthesis. Fluoroquinolones disrupt collagen synthesis and tenocyte viability, leading to tendinopathy and rupture risk. Conversely, disease-modifying antirheumatic drugs (DMARDs) and biologics modulate immune pathways, reducing inflammation and halting erosive joint damage. The interplay of pharmacokinetics, pharmacodynamics, genetic polymorphisms, and comorbidities determines individual risk profiles.

Risk Factors

Identifiable risk factors amplify vulnerability to drug-induced musculoskeletal complications. Dose and duration of exposure are critical—prolonged high-dose corticosteroids carry a higher risk of osteonecrosis and myopathy. Advanced age, female sex, pre-existing bone or muscle disease, renal insufficiency, and concurrent use of multiple myotoxic or osteotoxic agents further heighten risk. Genetic variants, such as SLCO1B1 polymorphisms, increase susceptibility to statin-induced myopathy. Awareness of these factors is essential for risk stratification and tailoring preventive strategies.

Clinical Features

The clinical spectrum of drug-related musculoskeletal manifestations ranges from mild arthralgias and myalgias to severe presentations such as rhabdomyolysis, avascular necrosis, pathological fractures, and tendon ruptures. Statin-associated muscle symptoms typically present as symmetrical proximal muscle pain or weakness, occasionally progressing to elevated creatine kinase and rhabdomyolysis. Glucocorticoid-induced osteoporosis is often asymptomatic until fracture occurs, while fluoroquinolone-induced tendinopathy manifests as acute pain, swelling, and functional impairment, predominantly affecting the Achilles tendon. Prompt recognition of these features is critical for mitigating morbidity.

Diagnosis

Diagnosis of drug-induced musculoskeletal disease is supported by a detailed history of medication exposure, temporal association with symptom onset, and exclusion of primary musculoskeletal or systemic disorders. Laboratory tests (e.g., creatine kinase for myopathy, bone turnover markers) and imaging modalities (DXA for bone density, MRI for avascular necrosis or tendon pathology) aid in assessment. Drug dechallenge and rechallenge may provide diagnostic clarity, although ethical and safety considerations apply. Clinicians should maintain a high index of suspicion in at-risk populations and employ structured causality assessment tools where appropriate.

Treatment & Management

Management strategies center on discontinuation or dose reduction of the offending agent, initiation of supportive or symptomatic therapies, and implementation of preventive measures. For glucocorticoid-induced osteoporosis, bisphosphonates, calcium, and vitamin D supplementation are standard, guided by fracture risk assessment. Statin-associated myopathy may warrant switching to alternative agents or lower doses, with coenzyme Q10 supplementation showing limited benefit. Tendinopathy necessitates cessation of fluoroquinolones and may require orthopedic intervention in cases of rupture. Multidisciplinary care, patient education, and regular monitoring are pivotal to optimizing outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the understanding and management of drug-induced musculoskeletal complications. Novel bone anabolic agents (romosozumab, abaloparatide) offer alternatives for refractory osteoporosis, including glucocorticoid-induced cases. Precision medicine approaches leveraging pharmacogenomics (e.g., SLCO1B1 genotyping for statins) enable personalized risk minimization. Monoclonal antibodies targeting RANKL (denosumab) and sclerostin have expanded the therapeutic armamentarium. Ongoing research into mitochondrial-targeted therapies and anti-inflammatory agents holds promise for mitigating drug-induced myopathies. Artificial intelligence-driven pharmacovigilance systems enhance early detection and intervention for adverse musculoskeletal events.

Guideline Recommendations

International guidelines from organizations such as the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) underscore the importance of baseline risk assessment, preventive pharmacotherapy, and regular monitoring for patients at risk of drug-induced musculoskeletal disease. Stratification tools (e.g., FRAX for fracture risk) inform decisions on prophylactic bisphosphonates in glucocorticoid users. Shared decision-making, patient education, and individualized therapy adjustments are emphasized for optimizing safety and efficacy. Multidisciplinary management is strongly advocated, particularly for complex or high-risk patients.

Conclusion

Drug exposure exerts a profound and multifaceted influence on the onset, progression, and management of musculoskeletal diseases. Clinicians must remain vigilant to the potential for iatrogenic musculoskeletal complications, particularly in vulnerable populations and in the context of polypharmacy. Advances in pharmacogenomics, targeted biologics, and risk stratification tools are enhancing the precision and safety of musculoskeletal care. Ongoing research and adherence to guideline-driven practice will be essential for minimizing harm and optimizing long-term musculoskeletal health in the era of expanding pharmacotherapy.